Publications by authors named "Brandusa Florica"
Introduction: Rheumatoid arthritis (RA) guidelines recommend methotrexate (MTX)-anchored therapy with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs); however, tolerability issues often lead to non-adherence. Canadian data on MTX tapering and/or withdrawal following b/tsDMARD initiation are minimal. This chart review assessed frequency of MTX tapering or withdrawal following b/tsDMARD initiation and the impact on disease status in Canadian adults with RA.
View Article and Find Full Text PDFArticle Synopsis
- The COMPLETE-PsA study evaluated the effectiveness of adalimumab (ADA) compared to nonbiologic disease-modifying antirheumatic drugs (nbDMARDs) in treating biologic-naïve Canadian adults with active psoriatic arthritis who had inadequate response to previous nbDMARD treatment.
- Conducted from 2012 to 2017, the study involved collecting data on various clinical measures and patient-reported outcomes, including disease activity scores and quality of life assessments.
- Results showed that ADA-treated patients had significantly better disease activity scores and health outcomes at 3 and 12 months, with quicker achievement of treatment milestones and lower rates of dactylitis compared to
Peripheral neuropathy in patients with systemic lupus erythematosus.
Semin Arthritis Rheum
October 2011
Objective: In patients with systemic lupus erythematosus (SLE), to determine 1) the prevalence and clinical features of peripheral neuropathies (PN) and whether they were SLE related, 2) whether there are associations between other SLE features and PN.
Methods: Patients who met the American College of Rheumatology case definition criteria for SLE peripheral neuropsychiatric syndromes were selected from the University of Toronto Lupus Clinic database. Demographic data and SLE-related clinical and laboratory data were extracted.